Confusion, a Rather Serious Adverse Drug Reaction with Valproic Acid: A Review of the French Pharmacovigilance Database

 

 Buy Article Permissions and Reprints

Abstract

Introduction: Confusion is an adverse drug reaction frequently observed with valproic acid. Some case reports are published in the literature but no systematic study from a sample of patients has been published. We performed this study in order to describe the main characteristics of this adverse drug reaction.

Methods: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.

Results: 272 cases of confusion were reported with valproic acid: 153 women and 119 men. Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%). It was “serious” for almost 2/3 of the patients (62.5%) and its outcome favourable in most of the cases (82%). The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.

Conclusion: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction. It occurs especially in older patients and during the first two weeks of treatment.

References

• 1 Alvarez-Gomez M, Vaamonde J, Narbona J. et al . Parkinsonian syndrome in childhood after sodium valproate administration.  Clin Neuropharmacol. 1993;  16 451-455
  PubMedGoogle Scholar
• 2 Armon C, Shin C, Miller P. et al . Reversible parkinsonism and cognitive impairment with chronic valproate use.  Neurology. 1996;  47 626-635
  CrossrefPubMedGoogle Scholar
• 3 Begaud B, Evreux J, Jouglard J. et al . Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France.  Therapie. 1985;  40 111-118
  PubMedGoogle Scholar
• 4 Begaud B, Martin K, Haramburu F. et al . Rates of spontaneous reporting of adverse drug reactions in France.  JAMA. 2002;  288 1588
  CrossrefPubMedGoogle Scholar
• 5 Belton K. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union.  Eur J Clin Pharmacol. 1997;  52 423-427
  CrossrefPubMedGoogle Scholar
• 6 Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients.  Ann Intern Med. 1995;  122 422-429
  PubMedGoogle Scholar
• 7 Cenraud B, Pautrizel B, Berets O. et al . Severe vigilance disturbances: a rare complication of sodium valproate treatment.  Rev Electroencephalogr Neurophysiol Clin. 1980;  10 376
  CrossrefPubMedGoogle Scholar
• 8 Dubois B. Mental Confusion. In: Godeau P, Herson S, Piette JC, ed. Traité de Médecine Interne 4ème édition. Paris: Médecine Sciences Flammarion 2004: 2441-2443
  Google Scholar
• 9 Durán-Ferreras E, Jiménez-Vilches PL, Galá-Barranco JM. et al . Hyperammonaemic encephalopathy due to valproic acid.  Rev Neurol. 2008;  46 537-539
  PubMedGoogle Scholar
• 10 Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management.  Lancet. 2000;  356 1255-1559
  Google Scholar
• 11 Ellaway C, Bennetts B, Tuck R. et al . Clumsiness, confusion, coma, and valproate.  Lancet. 1999;  535 1408
  PubMedGoogle Scholar
• 12 Gomceli YB, Kutlu G, Cavdar L. et al . Different clinical manifestations of hyperammonemic encephalopathy.  Epilepsy Behav. 2007;  10 583-587
  CrossrefPubMedGoogle Scholar
• 13 International Conference on Harmonisation . Guidance on addendum to E2C clinical safety data management: periodic safety update reports for marketed drugs.  Fed Regist. 2004;  69 5551-5552
  PubMedGoogle Scholar
• 14 Larrieu J, Lagueny A, Julien J. State of confusion induced by valproic acid and reversed after administration of clonazepam.  Rev Electroencephalogr Neurophysiol Clin. 1985;  15 179-184
  CrossrefPubMedGoogle Scholar
• 15 Marescaux C, Warter J, Micheletti G. et al . Stuporous episodes during treatment with sodium valproate: report of seven cases.  Epilepsia. 1982;  23 297-305
  CrossrefPubMedGoogle Scholar
• 16 Masmoudi K, Gras-Champel V, Masson H. et al . Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.  Pharmacopsychiatry. 2006;  39 9-12
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 MacCormick WC, Kukull WA, Belle G van. et al . Symptom patterns and comorbidity in the early stages of Alzheimer's disease.  J Am Geriatr Soc. 1994;  42 517-522
  PubMedGoogle Scholar
• 18 Montastruc JL, Sommet A, Lacroix I. et al . Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.  Joint Bone Spine. 2006;  73 629-632
  CrossrefPubMedGoogle Scholar
• 19 Onder G, Gambassi G, Scales C. et al . Adverse drug reactions and cognitive function among hospitalized older adults.  Eur J Clin Pharmacol. 2002;  58 371-377
  CrossrefPubMedGoogle Scholar
• 20 Owens MJ, Nemeroff CB. Pharmacology of valproate.  Psychopharmacol Bull. 2003;  37 17-24
  PubMedGoogle Scholar
• 21 Segura-Bruna N, Rodriguez-Campello A, Puente V. et al . Valproate-induced hyperammonemic encephalopathy.  Acta Neurol Scand. 2006;  114 1-7
  PubMedGoogle Scholar
• 22 Stephens J, Levy R. Effects of valproate and citrulline on ammonium-induced encephalopathy.  Epilepsia. 1994;  35 164-171
  CrossrefPubMedGoogle Scholar
• 23 Thiessard F, Roux E, Miremont-Salame G. et al . Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986–2001).  Drug Saf. 2005;  28 731-740
  CrossrefPubMedGoogle Scholar
• 24 Uthamalingam S, Kumar S, Vasudevan A. et al . Drowsiness and disorientation in a woman with depression.  J Am Geriatr Soc. 2005;  53 1638-9163
  CrossrefPubMedGoogle Scholar
• 25 Valproate .In: Sean C Sweetman, eds. Martindale. The Complete Drug Reference. 35th edition. London: Pharmaceutical Press 2007: 458-462
• 26 WHO Collaborating Centre for International Drug Monitoring .International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala: WHO 1992

Correspondence

E. Bondon-GuittonPharmD, PhD 

Laboratoire de Pharmacologie Médicale et Clinique

37 Allées Jules-Guesde

31000

Toulouse

France

Phone: +33/5/6114 59 18

Fax: +33/5/6125 51 16

Email: guitton@cict.fr